Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in women and girls with hereditary factor X deficiency.

Journal of thrombosis and haemostasis : JTH - 1 May 2018

Kulkarni R, James A H, Norton M, Shapiro A

Abstract excerpt

Essentials Plasma-derived factor X concentrate (pdFX) is used to treat hereditary factor X deficiency. pdFX pharmacokinetics, safety and efficacy were assessed in factor X-deficient women/girls. Treatment success rate was 98%; only 6 adverse events in 2 subjects were possibly pdFX related. On-demand pdFX 25 IU kg-1 was effective and safe in women/girls with factor X deficiency. SUMMARY: Background A high-purity,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation
Share to Coagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Europe

Share to Factor X

Share to Hemorrhage

Share to Severity of Illness Index

Share to Sex Factors

Share to United States

Source

Identifiers

PMID: 29460388
DOI: 10.1111/jth.13983

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in women and girls with hereditary factor X deficiency.PMID 29460388Read ↗

The History of Factor XIII Deficiency.Semantic proximity Read ↗

Diagnosis and treatment of inherited factor X deficiency.Semantic proximity Read ↗

Navigation of the Hemophilia Drug Choice-Paralysis: A Quick User Guide to New and Existing TherapiesSemantic proximity Read ↗

Emerging therapies for hemophilia: controversies and unanswered questionsSemantic proximity Read ↗

Review: Factor XI deficiency: review and management in pregnant women.Semantic proximity Read ↗

Clinical manifestations and management of life-threatening bleeding in the largest group of patients with severe factor XIII deficiency.Semantic proximity Read ↗

Regulation and importance of factor VIII levels in hemophilia A carriers.Semantic proximity Read ↗

The long and short of it: using the new factor products.Semantic proximity Read ↗

Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial.Semantic proximity Read ↗

Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet studySemantic proximity Read ↗

Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies.Semantic proximity Read ↗

[Hemophilia B replacement therapy drugs].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.